Dr. Reddy's flags semaglutide supply delay due to API quality issue

Monthly Volume DeclinedBusiness Updates View source PDF Explain this filing

DRREDDY · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-5.9%Reaction day

₹1351.10

prior close

₹1342.80

announcement price

In-mkt

timing

Nifty 100market+0.4%-6.3% vs market

Pharmaceuticals peers, median of 166sector+0.9%-6.9% vs sector

On the reaction day the stock moved 6.3 pts less than Nifty 100 and 6.9 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.0

10m

-0.2

15m

-1.0

30m

-1.7

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-5.9+0.4-6.3+0.9-6.9

Next day

-7.7+1.5-9.2+1.4-9.1

-8.5+1.4-9.9+1.8-10.3

-7.8+0.8-8.6+1.4-9.2

-9.0+1.0-10.0+1.6-10.5

-9.3+0.9-10.2+1.6-10.9

-9.6+1.6-11.2+1.2-10.8

15d

-15.3+2.0-17.3-0.5-14.8

-14.2+3.4-17.6+0.8-15.0

-15.3-1.0-14.2+2.7-18.0

-11.4-5.4-6.0-0.8-10.6

UpDownMarket · Nifty 100Sector · Pharmaceuticals peers, median of 166Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Dr. Reddy's found certain semaglutide batches out of specification due to an issue with the active pharmaceutical ingredient used in the product. The company is investigating the root cause. No impact on patient safety or existing global regulatory filings, but commercial supplies of semaglutide will be delayed until the issue is resolved. Management will host a conference call on July 9, 2026 at 16:30 IST to discuss further.

Likely market impact

Near-term revenue from semaglutide may be hit due to supply delays. No safety or regulatory risk flagged. Watch today's call for more details.